ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylaxis of respiratory viral infections, including COVID-19, rhinovirus and influenza in populations at risk of complications.